Search PubMed⌕ Search

Biomedical subjects

Z Guo

Publications and source records attributed to Z Guo.

488 records · Page 28Linked to original sources

Deletion of chromosome 3p is an early event in malignant progression of cervical cancer.

BACKGROUND: Loss of chromosome 3p has been reported to be a common genetic alteration in certain types of tumors as well as in cervical cancer. To understand its role in multistep cervical carcinogenesis, we analysed the allelic loss of this chromosome region in early pre-invasive cervical neoplastic lesions. MATERIALS AND METHODS: 49 cases comprising two types of pre-invasive lesions (without and with coexisting invasive cancer) were selected. Chromosome 3p deletios in selected neoplastic lesions were detected by PCR-RFLP combined with morphologically guided microdissection technique for DNA preparation. RESULTS: DNA samples from 40 cases out of 49 were successfully amplified and found to be heterozygotes at least in one chosen chromosome marker. Of 19 cases without coexisting cancer, LOH was detected in 4 cases(21%) and 3/17(18%) precancerous lesions (1 moderate dysplasia, 2 severe dysplasias) and 1/5(20%) carcinomas-in-situ. A significantly higher rate of allelic loss was observed in pre-invasive lesions adjacent to invasive cancer, showing 29%(4/14) in precancerous lesion and 67%(2/3) in carcinoma-in-situ. Analysing the invasive cancer and synchronous pre-invasive neoplasia, LOH was found to occur at early precursor stage in the majority of cases(5/7). The most frequently lost locus in cervical cancer is the chromosome regions detected by marker D3S30(60%) and D3F15S2(47%), suggesting a candidate tumor suppressor gene, which may play a role in cervical carcinogenesis, is harboured on this chromosome region. CONCLUSIONS: Our results confirm the high frequency of chromosome 3p allelic loss in cervical cancer and suggest that this genetic alteration is an early event in the development of cervical cancer and may potentially serve as a marker of risk for progression of premalignant lesions to invasive cancer.

Chromosomes, Human, Pair 3↗

The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter.

The cytomegalovirus(CMV) promoter is considered one of the strongest positive regulators. In this study toxicity, cell killing efficacy and bystander effect of Rous Sarcoma Virus(RSV) driven herpes simplex thymidine kinase(TK) gene therapy was compared with CMV driven TK gene therapy in three ovarian cancer cell lines with different growth patterns using a 3-(4,5-dimethylthiazol)-2,5-diphenyl tetra-zolium bromide (MTT) based assay. ADV/CMV-TK was shown to be 2 to 10 times more effective in tumor cell killing than ADV/RSV-TK. The difference in cell killing efficacy between ADV/CMV-TK and ADV/RSV-TK was dependent on the individual cell line. A CMV promoter dependent eight to ten fold improvement in cell killing efficacy was observed in the relatively slow growing SKOV3 cell line which is not easily transducible, while only a 2 to 4 fold difference was observed in the easily transducible OV-CA-2774 and OV-CA-1225 cell lines. ADV/CMV-TK also showed a stronger bystander effect than ADV/RSV-TK in all three ovarian cancer cell lines. Our data demonstrated that the efficacy of adenovirus-mediated gene therapy of ovarian cancer can be enhanced by using the CMV promoter without increasing toxicity.

Adenoviridae↗